Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting.
Renowned national specialists in multiple sclerosis (MS) met, for the eighth year in a row, to give details of the latest novelties presented at the last ECTRIMS Congress 2015, which are included in this review. One of the highlights at this Congress was the new classification of the phenotypes of MS. Both the diagnostic criteria of the neuromyelitis optica spectrum and the problems involved in the differential diagnosis derived from the lack of definition of the radiological spectrum were reviewed. The microbiota comes to the fore as a possible factor determining the disease, together with extrinsic factors such as tobacco, salt ingestion or vitamin D deficiency. Advances made in immunomodulation are driving the progress being made in the treatment of MS. Ocrelizumab is the first treatment with positive results in the primarily progressive forms and tocilizumab, a drug product for rheumatoid arthritis, stands out as a potential candidate for the treatment of neuromyelitis optica. Certain antibiotics and vitamins could also play a role in the treatment of MS. In this edition of the Congress special attention was paid to personalised therapy. To date, 11 drugs have been approved for use in Europe. There is a need for therapeutic algorithms that help us to choose the best treatment for each patient. Likewise, we need to be able to identify, in the early stages of the disease, the risk of developing disability, so as to be able to design therapeutic strategies. To do so, molecular biomarkers and other predictive tools are required. The problems that still exist in software technology in magnetic resonance hinder its application in daily clinical practice.
Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana.
O
O
Fernandez
Hospital de Basurto, 48013 Bilbao, Espana.
A
A
Rodriguez-Antiguedad
Hospital Donostia, 20014 San Sebastian, Espana.
J
J
Olascoaga
Hospital Clinico San Carlos, 28040 Madrid, Espana.
C
C
Oreja-Guevara
Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Espana.
J M
JM
Prieto
Hospital de Cruces, Baracaldo, Espana.
M M
MM
Mendibe-Bilbao
Hospital Universitario Puerta de Hierro-Majadahonda, 28035 Majadahonda, Espana.
J A
JA
Garcia-Merino
Hospital Universitari Dr. Josep Trueta, 17007 Girona, Espana.
Ll
L
Ramio-Torrenta
Fundacion Jimenez Diaz, 28040 Madrid, Espana.
R
R
Ginestal
Hospital Universitario Virgen de la Arrixaca., Murcia, Espana.
J E
JE
Meca-Lallana
Hospital General Universitari de Bellvitge, 08907 L'Hospitalet de Llobregat, Espana.
L
L
Romero-Pinel
Hospital Alvaro Cunqueiro, Vigo, Espana.
D
D
Munoz
Hospital Clinic de Barcelona. Institut Clinic de Malalties del Sistema Nervios, 08036 Barcelona, Espana.
A
A
Saiz
Hospital Universitari Son Espases, Palma de Mallorca, Espana.
M C
MC
Calles-Hernandez
Hospital Universitario Virgen Macarena, 41003 Sevilla, Espana.
G
G
Izquierdo
Hospital Ramon y Cajal, Madrid, Espana.
L M
LM
Villar
Hospital Universitario Central de Asturias, 33006 Oviedo, Espana.
P
P
Oliva-Nacarino
Hospital Universitario Virgen de las Nieves, 18013 Granada, Espana.
C
C
Arnal-Garcia
Hospitals Vall d'Hebron, 08035 Barcelona, Espana.
M
M
Comabella
Hospital Arnau de Vilanova, 25198 Lleida, Espana.
Ll
L
Brieva
Hospital Quiron, Pozuelo de Alarcon, Espana.
R
R
Arroyo
Hospitals Vall d'Hebron, 08035 Barcelona, Espana.
X
X
Montalban
D015415:Biomarkers; D003226:Congresses as Topic; D003937:Diagnosis, Differential; D005060:Europe; D006801:Humans; D009103:Multiple Sclerosis / Q000628:therapy*; D009471:Neuromyelitis Optica / Q000175:diagnosis* / Q000628:therapy*
D015415:Biomarkers